Aclarion Expands Commercial Team Amid Triple-Digit Growth in Nociscan Utilization
Aclarion granted inducement stock options to its new Western U.S. Commercial Director as demand for its Nociscan platform surges, reflecting strong adoption of its AI-driven chronic low back pain diagnostic tool.
Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in biomarker and AI-driven diagnostics for chronic low back pain, announced on May 6, 2026, that it has granted an inducement stock option to Daniel Keefe, its newly appointed Commercial Director for the Western United States. The grant, approved by the compensation committee on May 5, 2026, involves options to purchase 17,000 shares of common stock at an exercise price of $3.20 per share, equal to the closing price on the grant date. The options vest over four years, with one-fourth vesting on the first anniversary and the remainder monthly thereafter, contingent on continued employment.
The expansion of the commercial team comes as Aclarion reports triple-digit growth in utilization of its Nociscan platform, which uses magnetic resonance spectroscopy (MRS) data and proprietary augmented intelligence (AI) algorithms to help physicians identify painful versus nonpainful discs in the lumbar spine. The company’s cloud-based SaaS solution processes MRS data from MRI machines to extract chemical biomarkers associated with disc pain, providing critical insights to optimize treatment strategies for chronic low back pain—a condition affecting millions worldwide.
The inducement grant, structured under Nasdaq Listing Rule 5635(c)(4), underscores Aclarion’s commitment to strengthening its sales force in key regions. Keefe’s role as Western U.S. Commercial Director is expected to drive further adoption of Nociscan among healthcare providers, particularly as the platform gains traction for its noninvasive, evidence-based approach. The company’s focus on the Western region aligns with broader market trends, as demand for advanced diagnostic tools in pain management continues to rise.
The announcement highlights the growing importance of biomarker and AI technologies in clinical settings. By enabling physicians to pinpoint the source of low back pain with greater accuracy, Nociscan has the potential to improve treatment success rates and reduce reliance on invasive procedures. The triple-digit utilization growth suggests that the platform is resonating with clinicians seeking objective data to guide patient care.
Aclarion’s forward-looking statements caution that actual results may differ due to risks outlined in its SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025. However, the company’s recent commercial expansion indicates confidence in the market opportunity. For more information, visit www.aclarion.com. The latest updates on Aclarion are available at its newsroom.